<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04858997</url>
  </required_header>
  <id_info>
    <org_study_id>PAL-ZJCC-02</org_study_id>
    <nct_id>NCT04858997</nct_id>
  </id_info>
  <brief_title>Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients</brief_title>
  <official_title>An Open-label, Prospective Study of Tumor Response Time of Palbociclib in Combination With AI in Real-world First-line Treatment of Postmenopausal Chinese Patients With ER (+) HER2 (-) Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The international treatment guidelines now include recommendations for the use of CDK 4/6&#xD;
      inhibitors in combination with hormone agents for the treatment of postmenopausal women with&#xD;
      hormone-receptor-positive/HER2-negative ABC as the first-line standard therapy in endocrine&#xD;
      sensitive patients.&#xD;
&#xD;
      Nevertheless, it is generally thought that chemotherapy is associated with greater and&#xD;
      earlier tumor response, especially in case of high burden of disease. In a retrospective&#xD;
      analysis of real-world clinical practice (2002-2012) from US, only 60% of patients initiated&#xD;
      ET as the first treatment following metastatic diagnosis . In the real-life world of China, a&#xD;
      large number of HR+/HER2- ABC patients with non-visceral crisis also received chemotherapy in&#xD;
      first-line treatment, even though the ORR is similar compared with CDK4/6 inhibitors with&#xD;
      endocrine therapy. Zhejiang Cancer Hospital retrospective analysis of 5 cases of advanced&#xD;
      breast cancer first-line use of Ibance + ET, they were evaluated within 50 days (from 27days&#xD;
      to 50days).&#xD;
&#xD;
      Based on the early response time observed in real-world data mentioned above, it is proposed&#xD;
      a prospective study to further observe the tumor reduction rate in real-world, including to&#xD;
      identify the time of patient symptom improvement according to the quality of life scale.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the early assessment(4 weeks) , this prospective study comprehensively&#xD;
      investigate TTR of Palbociclib+ET in the first line treatment for HR+/HER2- MBC patients in&#xD;
      China real-world study.&#xD;
&#xD;
      Furthermore, evaluate the Early Tumor Shrinkage(ETS) of Palbociclib + ET, and assess&#xD;
      Treatment Free Interval (TFI) with TTR and ETS；TFI was analyzed at the following time points:&#xD;
      ≤24, &gt;24, ≤36, &gt; 36, ≤48, &gt;48 months.&#xD;
&#xD;
      Accroding to the follow-up of QoL questionnaire, understand the clinical symptoms&#xD;
      improvements time.&#xD;
&#xD;
      Meanwhile, cooperation with radiology department, establish a model for predicting early&#xD;
      response by observing the imaging and clinical pathological characteristics of patients with&#xD;
      ETS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early Tumor Shrinkage (ETS)</measure>
    <time_frame>4 weeks, 8weeks</time_frame>
    <description>10% change in the sum of the longest diameters (SLD) of target lesions at the first scan after 4weeks and 8weeks of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time To Response (TTR)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Time to first documented complete of partial response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>ORR is defined as the overall complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events per CTCAE version 4.03 and type</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Safety will be determined by type, severity of adverse events per CTCAE version 4.03 and type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Definitive 10% Deterioration in the Global Health Status/Quality of Life (QOL) Scale Score of the EORTC QLQ-C30</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>At least 10% relative to baseline worsening of the corresponding scale score (without further improvement above the threshold) or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Randomization to death from any cause, through the end of study (approximately 60months)]</time_frame>
    <description>time to death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Palbociclib-AI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ER(+)/HER2(-) patients with histologically or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease receive palbociclib PO daily on days 1-21, combined with AI as first-line treatment Disease assessments measured by CT imaging will be performed at first 4 weeks, 8weeks, then every 8weeks (± 7 days) from the date of randomization until radiographic/clinical documentation of progressive disease per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Palbociclib,125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment</description>
    <arm_group_label>Palbociclib-AI</arm_group_label>
    <other_name>Ibrabce</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AI</intervention_name>
    <description>AI, orally once daily (continuously)</description>
    <arm_group_label>Palbociclib-AI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult women (≥ 18 years of age) with proven diagnosis of adenocarcinoma of the breast&#xD;
             with evidence of locoregionally recurrent or metastatic disease not amenable to&#xD;
             resection or radiation therapy with curative intent and for whom chemotherapy is not&#xD;
             clinically indicated.&#xD;
&#xD;
          2. Documentation of histologically or cytologically confirmed diagnosis of&#xD;
             estrogen-receptor positive (ER+, &gt; 10%) breast cancer based on local laboratory&#xD;
             results.&#xD;
&#xD;
          3. Previously untreated with any systemic anti-cancer therapy for their locoregionally&#xD;
             recurrent or metastatic ER+ disease.&#xD;
&#xD;
          4. Postmenopausal women.&#xD;
&#xD;
          5. At least one measurable lesion as defined per RECIST v.1.1.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2.&#xD;
&#xD;
          7. Adequate organ and marrow function.&#xD;
&#xD;
          8. Willingness and ability to comply with scheduled visits, treatment plan, laboratory&#xD;
             tests, and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with advanced, symptomatic, visceral spread, that are at risk of&#xD;
             life-threatening complications including any of the following:&#xD;
&#xD;
               -  massive uncontrolled effusions [pleural, pericardial, peritoneal]&#xD;
&#xD;
               -  pulmonary lymphangitis,&#xD;
&#xD;
               -  over 50% liver involvement&#xD;
&#xD;
          2. Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis,or&#xD;
             leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or&#xD;
             progressive growth.&#xD;
&#xD;
          3. Prior neoadjuvant or adjuvant treatment with a non-steroidal aromatase inhibitor (ie,&#xD;
             anastrozole or letrozole) with disease recurrence while on or within 12 months of&#xD;
             completing treatment.&#xD;
&#xD;
          4. Prior treatment with any CDK4/6 inhibitor.&#xD;
&#xD;
          5. QTc &gt;480 msec (based on the mean value of the triplicate ECGs), family or personal&#xD;
             history of long or short QT syndrome, Brugada syndrome or known history of QTc&#xD;
             prolongation, or Torsade de Pointes (TdP).&#xD;
&#xD;
          6. Female patients who are pregnant or nursing.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>postmenopausal</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen-Ming Cao, Ph.D., M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Breast Medical Oncology, Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wen-Ming Cao, Ph.D., M.D.</last_name>
    <phone>8613858064001</phone>
    <email>caowm@zjcc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen-Ming Cao, Ph.D., M.D.</last_name>
      <phone>8613858064001</phone>
      <email>caowm@zjcc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Wen-Ming Cao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Borm GF, Tjan-Heijnen VC. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat. 2013 Oct;141(3):507-14. doi: 10.1007/s10549-013-2711-y. Epub 2013 Oct 9.</citation>
    <PMID>24104881</PMID>
  </results_reference>
  <results_reference>
    <citation>Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol. 2018 Aug 1;29(8):1634-1657. doi: 10.1093/annonc/mdy192.</citation>
    <PMID>30032243</PMID>
  </results_reference>
  <results_reference>
    <citation>Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016 Nov 17;375(20):1925-1936.</citation>
    <PMID>27959613</PMID>
  </results_reference>
  <results_reference>
    <citation>Swallow E, Zhang J, Thomason D, Tan RD, Kageleiry A, Signorovitch J. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012. Curr Med Res Opin. 2014 Aug;30(8):1537-45. doi: 10.1185/03007995.2014.908829. Epub 2014 Apr 14.</citation>
    <PMID>24669852</PMID>
  </results_reference>
  <results_reference>
    <citation>Turner NC, Finn RS, Martin M, Im SA, DeMichele A, Ettl J, Diéras V, Moulder S, Lipatov O, Colleoni M, Cristofanilli M, Lu DR, Mori A, Giorgetti C, Iyer S, Bartlett CH, Gelmon KA. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Ann Oncol. 2018 Mar 1;29(3):669-680. doi: 10.1093/annonc/mdx797.</citation>
    <PMID>29342248</PMID>
  </results_reference>
  <results_reference>
    <citation>Piessevaux H, Buyse M, Schlichting M, Van Cutsem E, Bokemeyer C, Heeger S, Tejpar S. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 2013 Oct 20;31(30):3764-75. doi: 10.1200/JCO.2012.42.8532. Epub 2013 Sep 16.</citation>
    <PMID>24043732</PMID>
  </results_reference>
  <results_reference>
    <citation>Wei M, Ye Q, Wang X, Wang M, Hu Y, Yang Y, Yang J, Cai J. Early tumor shrinkage served as a prognostic factor for patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy. Medicine (Baltimore). 2018 May;97(19):e0632. doi: 10.1097/MD.0000000000010632.</citation>
    <PMID>29742701</PMID>
  </results_reference>
  <results_reference>
    <citation>Grünwald V, Lin X, Kalanovic D, Simantov R. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. Eur Urol. 2016 Dec;70(6):1006-1015. doi: 10.1016/j.eururo.2016.05.010. Epub 2016 May 26.</citation>
    <PMID>27238653</PMID>
  </results_reference>
  <results_reference>
    <citation>Janni W, Alba E, Bachelot T, Diab S, Gil-Gil M, Beck TJ, Ryvo L, Lopez R, Tsai M, Esteva FJ, Auñón PZ, Kral Z, Ward P, Richards P, Pluard TJ, Sutradhar S, Miller M, Campone M. First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial. Breast Cancer Res Treat. 2018 Jun;169(3):469-479. doi: 10.1007/s10549-017-4658-x. Epub 2018 Feb 5.</citation>
    <PMID>29404806</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>April 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

